[
  {
    "ts": null,
    "headline": "Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi",
    "summary": "Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.",
    "url": "https://finnhub.io/api/news?id=783f56df13b7dc5876faba6bdbf3b2c9c3036249e20be83de1a1eea8cc2b3dc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744818540,
      "headline": "Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi",
      "id": 133942922,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.",
      "url": "https://finnhub.io/api/news?id=783f56df13b7dc5876faba6bdbf3b2c9c3036249e20be83de1a1eea8cc2b3dc3"
    }
  },
  {
    "ts": null,
    "headline": "EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s",
    "summary": "The antibody is now approved for treating adults diagnosed with mild cognitive impairment and mild dementia.",
    "url": "https://finnhub.io/api/news?id=5628000ce90451ad3feba63dc3921af7e60038a76d85ce0805109cef259256cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744811148,
      "headline": "EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s",
      "id": 133936140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The antibody is now approved for treating adults diagnosed with mild cognitive impairment and mild dementia.",
      "url": "https://finnhub.io/api/news?id=5628000ce90451ad3feba63dc3921af7e60038a76d85ce0805109cef259256cc"
    }
  }
]